-
GenEditBio to Present New Pre-Clinical Data for its Genome Editing and Delivery Platforms at the 27th Annual Meeting of the American Society of Gene and Cell Therapy
GenEditBio Limited (“GenEditBio”), a biotechnology start-up company focusing on genome-editing therapeutic solutions through the discovery of novel Cas nuclease and the development of safe and efficient cargo delivery platforms, today announced that the Company will have three poster presentations of pre-clinical data across platforms at the upcoming 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) to take place in Baltimore, Maryland, USA, May 8-11, 2024.
넶0 2024-04-30 -
引正基因完成新一轮融资,专注下一代基因编辑工具
2024年4月4日,基因编辑平台型技术企业引正基因科技有限公司(下称“引正基因”,GenEditBio)宣布完成千万美元的Pre-A+轮融资。
넶207 2024-04-04 -
Dr ZHU Tian Participated in Panel Discussion on Healthtech Innovations at Hong Kong Pavilion during LEAP 2024
Our Co-Founder and CEO, Dr. ZHU Tian (second from left), recently participated in a panel discussion on “Hong Kong Healthtech Innovations Drive Global Transformation for Generations to Come” at the Hong Kong Pavilion LEAP 2024 in Riyadh, Saudi Arabia on 4 March 2024.
넶68 2024-03-06 -
GenEditBio closes angel and pre-A rounds of funding to develop gene-editing tools
GenEditBio Limited (“GenEditBio”), which was established in 2021 and has laboratories and offices in Beijing, Hong Kong and Boston, has raised tens of millions of U.S. dollars in angel and series pre-A funding to develop next-generation gene-editing tools and advance its pipelines.
넶597 2022-05-29 -
Dr. Zongli Zheng attended the CSHL (Cold Spring Harbour Laboratory) Genome Engineering Conference 2022
In August 2022, Dr. Zheng attended the eighth Cold Spring Harbour meeting on Genome Engineering: CRISPR Frontiers.
넶181 2022-08-23